BioLamina AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioLamina AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11241
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioLamina AB (BioLamina) is a biotechnology company that focuses on the development, manufacture and distribution of cell culture reagents intended for culturing primary cells. The company offers a wide portfolio of chemically defined and xeno-free laminin proteins. Its product portfolio includes Laminin-521, a recombinant human protein, which is the natural laminin for pluripotent stem cells; Laminin-111, for early epithelial development and differentiation of the epiblast; and LAMscreen. BioLamina’s products find application in maintaining skeletal muscle cells; kidney, intestinal and endothelial cells; cancer cells, animal stem cells and other neural cells. The company offers its products through a network of distributors in Asia, Europe and the Americas, among others. BioLamina is headquartered in Stockholm, Sweden.

BioLamina AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioLamina AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
BioLamina AB, Medical Devices Deals, 2012 to YTD 2018 9
BioLamina AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BioLamina AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
BioLamina and Novo Nordisk Enter into Partnership 11
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 12
Licensing Agreements 13
BioLamina Enters into Licensing Agreement with Cevec Pharma 13
BioLamina Enters Into Licensing Agreement With Vitrolife For Cryopreservation Medium 14
Acquisition 15
Vitrolife Acquires 4.6% Stake In Biolamina For US$0.6 Million 15
BioLamina AB – Key Competitors 16
BioLamina AB – Key Employees 17
BioLamina AB – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Product News 19
May 02, 2018: BioLamina Launches a Cell Therapy Grade Stem Cell Culture Matrix, Biolaminin 521 CTG, Bridging Discovery and Clinical Cell Therapy 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
BioLamina AB, Pharmaceuticals & Healthcare, Key Facts 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioLamina AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioLamina AB, Deals By Therapy Area, 2012 to YTD 2018 8
BioLamina AB, Medical Devices Deals, 2012 to YTD 2018 9
BioLamina AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
BioLamina and Novo Nordisk Enter into Partnership 11
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 12
BioLamina Enters into Licensing Agreement with Cevec Pharma 13
BioLamina Enters Into Licensing Agreement With Vitrolife For Cryopreservation Medium 14
Vitrolife Acquires 4.6% Stake In Biolamina For US$0.6 Million 15
BioLamina AB, Key Competitors 16
BioLamina AB, Key Employees 17
BioLamina AB, Subsidiaries 18

List of Figures
BioLamina AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioLamina AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
BioLamina AB, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[BioLamina AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Marine Harvest ASA:企業のM&A・事業提携・投資動向
    Marine Harvest ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Marine Harvest ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Yingli Green Energy Holding Company Limited (YGE):電力:M&Aディール及び事業提携情報
    Summary Yingli Green Energy Holding Company Limited (Yingli Solar) is a solar panel manufacturer. It designs, assembles, sells, and installs solar PV systems. It covers the entire value chain of solar PV industry ranging from designing to manufacturing of multicrystalline polysilicon ingots, wafers, …
  • Calumet Specialty Products Partners LP (CLMT):企業の財務・戦略的SWOT分析
    Calumet Specialty Products Partners LP (CLMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • McDermott International Inc (MDR):電力:M&Aディール及び事業提携情報
    Summary McDermott International Inc (MII) is a provider of integrated engineering, procurement, construction and installation (EPCI), front-end engineering and design (FEED) and module fabrication services for upstream field developments. It delivers fixed and floating production facilities, pipelin …
  • Essilor International S.A.:企業の戦略・SWOT・財務分析
    Essilor International S.A. - Strategy, SWOT and Corporate Finance Report Summary Essilor International S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • National Bank Of Kuwait Sak
    National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Qiagen Marseille SA-医療機器分野:企業M&A・提携分析
    Summary Qiagen Marseille SA (HalioDx), formerly Ipsogen SA is a subsidiary of Qiagen NV, a drugs manufacturing company that develops and markets molecular diagnostic tests. The company offers products for the treatment of chronic myeloid, chronic lymphocytic, acute myeloid, and acute lymphoblastic l …
  • MGM China Holdings Ltd:企業の戦略・SWOT・財務情報
    MGM China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary MGM China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Molinos Rio de la Plata SA (MOLI3):企業の財務・戦略的SWOT分析
    Molinos Rio de la Plata SA (MOLI3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Nisshinbo Holdings Inc. (3105):企業の財務・戦略的SWOT分析
    Nisshinbo Holdings Inc. (3105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • Nippon Paint (China) Co Ltd:企業の戦略・SWOT・財務分析
    Nippon Paint (China) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nippon Paint (China) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Trillion Energy International Inc (PKPL):企業の財務・戦略的SWOT分析
    Summary Trillion Energy International Inc (Trillion Energy) formerly Park Place Energy Inc, is an oil and gas company that offers exploration and development of oil and natural gas. The company offers various oil and gas services such as drilling, exploration, development, production, distribution a …
  • Sensus Healthcare Inc (SRTS):企業の製品パイプライン分析2018
    Summary Sensus Healthcare Inc (Sensus) designs, manufactures and markets proprietary medical devices for the treatment of various types of cancers and skin diseases. The company offers superficial radiation therapy (SRT) technology based non-surgical treatment options for patients suffering from var …
  • Cooper Tire & Rubber Co (CTB):企業の財務・戦略的SWOT分析
    Cooper Tire & Rubber Co (CTB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Premaitha Health Plc (NIPT)-製薬・医療分野:企業M&A・提携分析
    Summary Premaitha Health Plc (Premaitha Health), formerly Vialogy Plc, is a molecular diagnostics company, which focuses on the development of genetic screening tests including novel tests for non-invasive prenatal screening (NIPT). Its flagship product, the IONA test is an advanced NIPT test that a …
  • Motorola Solutions Inc (MSI):企業の財務・戦略的SWOT分析
    Motorola Solutions Inc (MSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Shoaibi Group:石油・ガス:M&Aディール及び事業提携情報
    Summary Shoaibi Group (Shoaibi) is a provider of manufacturing, services, product distribution and investment programs. The company provides active venture capital and private equity investments. It offers services such as marketing and technical services, finance and taxation, public relations, adm …
  • Franklin Resources, Inc.:企業のM&A・事業提携・投資動向
    Franklin Resources, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Franklin Resources, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Formosa Petrochemical Corp (6505):石油・ガス:M&Aディール及び事業提携情報
    Summary Formosa Petrochemical Corp (FPCC) refines crude oil and sells refined petroleum products and olefins. The company operates refinery and integrated petrochemical complexes. It imports, exports, markets, stores, and transports crude oil, gasoline, naphtha, propane and other feed stocks. The co …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆